FDA ap­proves Dai­ichi Sanky­o's new first-line AML drug quizar­tinib with boxed warn­ing for heart dis­or­ders

Pa­tients with a rar­er form of acute myeloid leukemia now have a front­line treat­ment op­tion for the first time, thanks to the FDA’s ap­proval of Van­fly­ta (quizar­tinib), Dai­ichi Sankyo an­nounced late Thurs­day.

Van­fly­ta has been ap­proved for FLT3-ITD-pos­i­tive AML pa­tients in com­bi­na­tion with chemo and as a main­te­nance monother­a­py af­ter ini­tial treat­ment. The agency al­so ap­proved a com­pan­ion di­ag­nos­tic to de­tect the mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER